ASND - Ascendis Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
66.50
-1.00 (-1.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close67.50
Open67.94
Bid1.00 x 1000
Ask199,999.98 x 1200
Day's Range65.93 - 67.94
52 Week Range31.56 - 76.99
Volume145,596
Avg. Volume130,654
Market Cap2.782B
Beta0.85
PE Ratio (TTM)N/A
EPS (TTM)-4.11
Earnings DateAug 29, 2017 - Sep 4, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est79.70
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced its support of “Children’s Growth Awareness Week” taking place September 16-22, 2018, as a part of the company’s commitment to patients and to improving the lives of people with growth disorders. This initiative will be celebrated worldwide as “International Children's Growth Awareness Day” on September 20, 2018. 489, a resolution recognizing and supporting the goals and ideals of a “Growth Awareness Week,” to increase awareness in the community about the importance of what a child’s growth pattern can say about overall health.

  • Thomson Reuters StreetEvents13 days ago

    Edited Transcript of ASND earnings conference call or presentation 29-Aug-18 8:30pm GMT

    Q2 2018 Ascendis Pharma A/S Earnings Call

  • GlobeNewswire18 days ago

    Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences

    COPENHAGEN, Denmark, Sept. 06, 2018-- Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced upcoming ...

  • GlobeNewswire24 days ago

    Ascendis Pharma A/S Announces Upcoming Investor Presentations

    COPENHAGEN, Denmark, Aug. 31, 2018-- Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the ...

  • Ascendis Pharma (ASND) Q2 2018 Earnings Conference Call Transcript
    Motley Fool24 days ago

    Ascendis Pharma (ASND) Q2 2018 Earnings Conference Call Transcript

    ASND earnings call for the period ending June 30, 2018.

  • GlobeNewswire26 days ago

    Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results

    -Continued advancement of endocrinology rare disease pipeline, paving way for application of TransCon™ technology in a new therapeutic area-. -Conference Call Today at 4:30 p.m. Eastern Time-. COPENHAGEN, ...

  • ACCESSWIRE26 days ago

    Ascendis Pharma A/S Sponsored ADR to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 29, 2018 / Ascendis Pharma A/S Sponsored ADR (NASDAQ: ASND ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 29, 2018 at 4:30 ...

  • GlobeNewswirelast month

    Ascendis Pharma A/S Announces Second Quarter 2018 Financial Results and Business Update Conference Call on August 29

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, August 29, 2018 at 4:30 p.m. Eastern Time (ET) to review its second quarter 2018 financial results and provide a business update. A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative prodrug technology to build a leading, fully integrated rare disease company focused on making a meaningful difference in patients’ lives.

  • GlobeNewswire2 months ago

    Ascendis Pharma A/S Announces Participation in the 2018 Wedbush PacGrow Healthcare Conference

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the company will participate in an upcoming investor conference. A live webcast of the event will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com.  A webcast replay will also be available on this website shortly after conclusion the event for 30 days. Ascendis Pharma is applying its innovative prodrug technology to build a leading, fully integrated rare disease company focused on making a meaningful difference in patients’ lives.

  • GlobeNewswire2 months ago

    Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual Meeting

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced a poster presentation on its TransCon technology at the annual meeting of the Controlled Release Society, taking place in New York City, July 22-24. Ascendis Pharma currently has three rare disease endocrinology product candidates in clinical development using the TransCon technology platform.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ASND earnings conference call or presentation 30-May-18 8:30pm GMT

    Q1 2018 Ascendis Pharma A/S Earnings Call

  • ACCESSWIRE5 months ago

    Wired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNP

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Ascendis Pharma A/S (NASDAQ: ASND), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ASND as the Company's latest news hit the wire. On May 08, 2018, the Denmark-based biopharmaceutical Company announced that it has dosed the first subjects in a first-in-human Phase-1 trial of TransCon CNP, a long-acting prodrug of a C-type natriuretic peptide (CNP) in development as a therapeutic option for achondroplasia and potentially for other fibroblast growth factor receptor (FGFR)-related skeletal disorders. Active-Investors.com is currently working on the research report for Audentes Therapeutics, Inc. (NASDAQ: BOLD), which also belongs to the Healthcare sector as the Company Ascendis Pharma.

  • Five Stocks To Buy According To Top Biotech-Focused Funds
    Insider Monkey5 months ago

    Five Stocks To Buy According To Top Biotech-Focused Funds

    Biotechnology is a very interesting industry to invest in, but also very complex. If you are looking for stocks that are most likely to see their value surge, then your best bet would be to start with biotech companies. The industry focuses on development of novel therapies and drugs that can treat various conditions, therefore […]

  • Reuters5 months ago

    High-profile investors bet on stocks tied to millennials - Sohn Conference

    Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday that they said should benefit from the growing clout of the millennial generation, ranging from online food ordering to homebuilders. John Khoury, founder and managing partner of the $2.7 billion (£1.94 billion) Long Pond Capital hedge fund, revealed a long position in U.S. homebuilder D.R. Horton Inc (DHI.N), which he said should rise as more millennials age into the first-time home buyer market.

  • Reuters5 months ago

    High-profile investors bet on stocks tied to millennials - Sohn Conference

    Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas on Monday that they said should benefit from the growing clout of the millennial generation, ranging from online food ordering to homebuilders. John Khoury, founder and managing partner of the $2.7 billion (£1.94 billion) Long Pond Capital hedge fund, revealed a long position in U.S. homebuilder D.R. Horton Inc (DHI.N), which he said should rise as more millennials age into the first-time home buyer market.

  • CNBC5 months ago

    Here are the stock picks from the rising hedge fund stars at Sohn

    The Sohn Investment Conference in New York kicked off Monday with hedge fund managers' picks moving markets. Sohn is the most widely anticipated hedge fund event of the year, where managers volunteer their time and best investment ideas to raise money in the fight against childhood cancer. This year, the conference began with Next Wave Sohn, featuring the "next generation of talent" among hedge fund managers.